APA (7th ed.) Citation

Maxim Grymonprez, Tine L. De Backer, Xander Bertels, Stephane Steurbaut, Stephane Steurbaut, Lies Lahousse, & Lies Lahousse. (2023). Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Maxim Grymonprez, Tine L. De Backer, Xander Bertels, Stephane Steurbaut, Stephane Steurbaut, Lies Lahousse, and Lies Lahousse. Long-term Comparative Effectiveness and Safety of Dabigatran, Rivaroxaban, Apixaban and Edoxaban in Patients with Atrial Fibrillation: A Nationwide Cohort Study. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Maxim Grymonprez, et al. Long-term Comparative Effectiveness and Safety of Dabigatran, Rivaroxaban, Apixaban and Edoxaban in Patients with Atrial Fibrillation: A Nationwide Cohort Study. Frontiers Media S.A., 2023.